Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Expedited Review Pathways: Three More Breakthroughs, Third RMAT Awarded

May 14 2017

• By Bridget Silverman

Bacterias 3D rendering

Related Content

Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar

Apr 24 2017

Proteon Therapeutics Slumps On Phase III Study Miss In CKD

Dec 14 2016

US FDA First's RMAT Designation: Humacyte Got A 'Quick Response'

Mar 26 2017

Seres Argues Different Diagnostic Needed In Recurrent C. Difficile Trials

Feb 01 2017

Corbus Cystic Fibrosis Data May Justify Longer, Larger Study

Mar 31 2017

Vericel Jumps On Positive Heart Failure Data

Mar 11 2016

Horizon's Poor Primary Care Performance Overshadows River Vision Buy

May 09 2017

Roche reject recycled for ophthalmic indication

Jun 13 2013

Related Companies

Theriva Biologics, Inc.

Proteon Therapeutics, Inc

River Vision Development Corp.

Horizon Therapeutics plc

Vericel Corporation

Rebiotix, Inc.

Seres Therapeutics, Inc.

Merck & Co., Inc.

Roche Holding AG

Additional Topics

United States Review Pathway Regulation BioPharmaceutical

More from Review Pathways

More from Pathways & Standards

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window